CoChat
Sign Up
Cited by 7Pituitary Gland Disorders and TreatmentsGrowth Hormone and Insulin-like Growth FactorsHypothalamic control of reproductive hormones

Growth hormone replacement therapy in childhood-onset craniopharyngioma

Open access
van Iersel, Laura, van Schaik, Jiska, van Santen, Hanneke M.·2025·Best Practice & Research Clinical Endocrinology & Metabolism
DOI 10.1016/j.beem.2025.101998
Open this paper in CoChat — free account

Abstract

Tumour- or treatment related growth hormone (GH) deficiency is often observed in children diagnosed or treated for childhood onset craniopharyngioma (cCP). Adequate and timely GH replacement therapy (GHRT) is important to improve growth velocity and final height during childhood. GHRT may be continued through adulthood due to its beneficial effects on metabolic health, bone health, mental health and quality of life. The current evidence suggests no increased risk for tumour progression or recurrence, secondary neoplasms or mortality in cCP patients receiving GHRT. In children with newly diagnosed cCP, GHRT may be initiated as early as three months after initial surgery to ameliorate linear growth and metabolic disturbances. The potential long-term effects of early initiation of GHRT as well GHRT with long-acting GH preparations are topics for future research.

Integrity signals

Registry

Crossref · 10.1016/j.beem.2025.101998

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ongoing accumulating evidence supports the safety of GH replacement.

    “Ongoing accumulating evidence of the safety of GH replacement has led to more recent guidelines (29) and other reviews (30)”

    From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [30]

  • Recent guidelines suggest initiation of GH as early as 3 months post completion of therapy in individuals with craniopharyngioma.

    “suggesting initiation as early as 3 months post completion of therapy in individuals with craniopharyngioma.”

    From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [30]

Cites

Flagged first, then by citations

1 of the 91 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
van Iersel, L., van Schaik, J., & van Santen, H. M.
Venue
Best Practice & Research Clinical Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2025-09
Volume
39
Issue
5
Pages
101998
ISSN
1521-690X (ISSN-L)
DOI
10.1016/j.beem.2025.101998
OpenAlex
W4409535088
Cited by
6
References
91
Citations by year
2026: 3 · 2025: 3
FWCI
0.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Best Practice & Research Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
growth hormone replacement therapy, childhood-onset craniopharyngioma, growth hormone deficiency, linear growth, adult height, early treatment, tumor progression, secondary malignancies, bone health, metabolic health, quality of life
MeSH terms
Child, Craniopharyngioma, Growth Disorders, Humans, Pituitary Neoplasms, Human Growth Hormone, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review